PMID- 25899805
OWN - NLM
STAT- MEDLINE
DCOM- 20160624
LR  - 20181113
IS  - 1573-2576 (Electronic)
IS  - 0360-3997 (Linking)
VI  - 38
IP  - 5
DP  - 2015 Oct
TI  - Anti-Inflammatory Effects of Lysozyme Against HMGB1 in Human Endothelial Cells 
      and in Mice.
PG  - 1911-24
LID - 10.1007/s10753-015-0171-8 [doi]
AB  - High mobility group box 1 (HMGB1) was recently shown to be an important 
      extracellular mediator of severe vascular inflammatory disease, sepsis. Lysozyme 
      protects us from the ever-present danger of bacterial infection and binds to 
      bacterial lipopolysaccharide (LPS) with a high affinity. Here, we show, for the 
      first time, the anti-septic effects of lysozyme in HMGB1-mediated inflammatory 
      responses in vitro and in vivo. The data showed that lysozyme posttreatment 
      suppressed LPS-mediated release of HMGB1 and HMGB1-mediated cytoskeletal 
      rearrangement. Lysozyme also inhibited HMGB1-mediated hyperpermeability and 
      leukocyte migration in human endothelial cells. In addition, lysozyme inhibited 
      the HMGB1-mediated activation of Akt, nuclear factor-kappaB (NF-kappaB), extracellular 
      regulated kinases (ERK) 1/2 and production of interleukin (IL)-1beta, IL-6, tumor 
      necrosis factor-alpha (TNF-alpha), and chemoattractant protein-1 (MCP-1) in HUVECs. 
      Furthermore, lysozyme reduced the cecal ligation and puncture (CLP)-induced 
      release of HMGB1, migration of leukocytes, septic mortality, and pulmonary damage 
      in mice. Collectively, these results suggest lysozyme as a candidate therapeutic 
      agent for the treatment of vascular inflammatory diseases via inhibition of the 
      HMGB1 signaling pathway.
FAU - Lee, Wonhwa
AU  - Lee W
AD  - College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, 
      Kyungpook National University, 80 Daehak-ro, Buk-gu, Daegu, 702-701, Republic of 
      Korea.
FAU - Ku, Sae-Kwang
AU  - Ku SK
FAU - Na, Dong Hee
AU  - Na DH
FAU - Bae, Jong-Sup
AU  - Bae JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Inflammation
JT  - Inflammation
JID - 7600105
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (HMGB1 Protein)
RN  - 0 (HMGB1 protein, human)
RN  - EC 3.2.1.17 (Muramidase)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Chickens
MH  - Dose-Response Relationship, Drug
MH  - Endothelium, Vascular/*drug effects/metabolism
MH  - HMGB1 Protein/*antagonists & inhibitors/*metabolism
MH  - Human Umbilical Vein Endothelial Cells/drug effects/metabolism
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Muramidase/*pharmacology
EDAT- 2015/04/23 06:00
MHDA- 2016/06/25 06:00
CRDT- 2015/04/23 06:00
PHST- 2015/04/23 06:00 [entrez]
PHST- 2015/04/23 06:00 [pubmed]
PHST- 2016/06/25 06:00 [medline]
AID - 10.1007/s10753-015-0171-8 [doi]
PST - ppublish
SO  - Inflammation. 2015 Oct;38(5):1911-24. doi: 10.1007/s10753-015-0171-8.